Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2013

View Archived Issues

Chugai Pharmaceutical updates progress of second quarter 2013

Daiichi Sankyo set to expand drug discovery program

KU Leuven and Fit Biotech to collaborate on novel immunotherapeutics

Inhibition of FXII activation shows potential for thromboprophylaxis

Novel mutation in the CACNA1H gene identified in classic idiopathic generalized epilepsies

Novel tool to analyze drug and target binding optimization in cells and tissues

Antitope and ChemomAb to generate human antibodies against inflammatory diseases

Researchers identify CGRP receptor gene SNPs associated with migraine

Chelsea Therapeutics provides update on Northera NDA

MDxHealth and Bostwick enter marketing agreement for prostate cancer diagnostic

Pfizer reports pipeline developments of second quarter 2013

Norgine discontinues development of NRL-972

Teva reports formation of global Huntington's disease research collaboration

MC-710 shows safety and efficacy in phase II trials in patients with hemophilia

Researchers at Bayer design new sGC and PDE5 inhibitors

Novel PBK/Akt inhibitors for cancer presented by Bayer

Ajinomoto Pharmaceuticals discontinues development of AJG-501

Isis earns milestone from GSK for advancement of ISIS-TTR Rx program

Catabasis reports encouraging results from phase I trial of CAT-2003

ImmunoCellular Therapeutics' anticancer vaccine enters phase I trial in recurrent GBM

AstraZeneca and FibroGen enter collaboration for FG-4592

Flutiform recommended for approval in Japan

Adasuve launched in Europe for agitation in patients with schizophrenia or bipolar disorder

AEterna Zentaris initiates phase III trial of zoptarelin doxorubicin for endometrial cancer

Elusys reports data on Anthim given via intramuscular administration to anthrax-exposed animals

Phase IIa rheumatoid arthritis study planned for RHB-104

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...